Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.90 -0.18 (-0.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
31 32 Next >
Why Bristol-Myers Squibb Shares Are Trading Higher Today
Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced a $5 billion buyback and issued FY22 financial guidance. Bristol-Myers said it... 
Via Benzinga
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to... 
Via Benzinga
Bristol-Myers Squibb's Debt Overview
Shares of Bristol-Myers Squibb (NYSE:BMY) increased by 8.89% in the past three months. Before having a look at the importance of debt, let us look at how much debt Bristol-... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
53 Firms Going Ex-Dividend Next Week, Including Comcast, AT&T And General Mills
There are several well known large cap stocks going ex-dividend next week including nine of our Top 100 Dividend Stocks. 
Via Talk Markets
Weakness Is Turning Into Opportunity For Bristol Myers Squibb
With plenty of strong catalysts, shares of BMY are just beginning to pivot higher. 
Via Talk Markets
Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns
Bristol-Myers Squibb offers a substantial dividend, but that's far from the only reason that BMY stock is a great investment for 2022. 
Via InvestorPlace
7 Dividend Increases Expected In January 2022
How many dividend increases are you going to receive this month? How many stocks on this list do you own? Are you ready to crush it in 2022? 
Via Talk Markets
Market Trend: Erratic And Unreliable
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
Peering Into Bristol-myers Squibb Company's Recent Short Interest
Bristol-myers Squibb Company's (NYSE:BMY) short percent of float has risen 14.13% since last its last report. The company recently reported that it has 23.26 million shares sold... 
Via Benzinga
Best Stocks For Wheel Strategy Trades: Use These In 2022
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy. 
Via Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Buy Time: Dirt Cheap, Pays A Market-Beating Yield, And Just Announced A $15 Billion Share Buyback
The US stock market’s resilience is amazing. It started off November with a hard dip in response to the Omicron variant news. 
Via Talk Markets
Dreaming Of A Red Christmas
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some... 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
FDA Approves Bristol Myers' Orencia As First Drug To Prevent Graft-Versus-Host Disease
The FDA approved Bristol Myers Squibb & Co's (NYSE: BMY) Orencia (abatacept) for the prevention of acute graft-versus-host disease (GVHD) in combination... 
Via Benzinga
CNBC's Final Trades: Darden Restaurants, Bristol-Myers Squibb, AIG, And This Stock Which Is The Biggest Breakout
On CNBC’s “H... 
Via Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
To sell or not to sell?
Pfizer says its covid pill is 90% effective. PFE got higher target prices from Berenburg and Mizuho 
Via Talk Markets
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... 
Via Benzinga
Why Bristol-Myers Squibb Shares Are Rising Today
Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced an additional $15 billion buyback and raised its quarterly dividend. Bristol-Myers... 
Via Benzinga
As We Come Towards The End Of The Trading Year, A Round Up Of Four Recent Stocks
As we come towards the end of another trading year I thought it would be a good idea to catch up on some of the more recent stocks I have analyzed and in no particular order. 
Via Talk Markets
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
5 Dividend Growth Stocks Getting Crushed… Time To Buy?
We have a disconnect between business performance and stock performance. And we have a disconnect between individual stocks and the stock market. These disconnects could lead us to fantastic long-term... 
Via Talk Markets
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. 
Via InvestorPlace
Exposures COVID-19
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.